Pathogenesis of HIV disease: Opportunities for new prevention interventions

Clinical Infectious Diseases

Volumn 45, Issue SUPPL. 4, 2007, Pages

  Fauci, Anthony S ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; MICROBICIDE;

CHEMOPROPHYLAXIS; CIRCUMCISION; CLINICAL TRIAL; DISEASE COURSE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION RISK; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; VIRUS LOAD; VIRUS TRANSMISSION;

AIDS VACCINES; ANTI-HIV AGENTS; ANTI-INFECTIVE AGENTS, LOCAL; CHEMOPREVENTION; CIRCUMCISION, MALE; FEMALE; HIV; HIV INFECTIONS; HUMANS; MALE; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; SEXUAL BEHAVIOR; VIRAL LOAD;

EID: 40949165392     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/522540     Document Type: Review

References (40)

1. Centers for Disease Control and Prevention (CDC). A glance at the HIV/AIDS epidemic. Rev. ed. Atlanta, GA: US Department of Health and Human Services, CDC, 2007. Available at: http://www.cdc.gov/hiv/resources/ factsheets/PDF/At-A-Glance.pdf. Accessed 11 October 2007.
2. Joint United Nations Program on AIDS, World Health Organization. AIDS epidemic update. December 2006. Available at: http://www.unaids.org/en/ HIV_data/epi2006/default.asp. Accessed 30 January 2007.
3. Hanssens C. Legal and ethical implications of opt-out HIV testing. Clin Infect Dis 2007; 45(Suppl 4):S232-9 (in this supplement).
4. Pope M, Haase AT. Transmission, acute HIV-1 infection and the quest for strategies to prevent infection. Nat Med 2003; 9:847-52.
5. Lederman MM, Offord RE, Hartley O. Microbicides and other topical strategies to prevent vaginal transmission of HIV. Nat Rev Immunol 2006; 6:371-82.
6. Fauci AS, Lane HC. Human immunodeficiency virus (HIV) disease: AIDS and related disorders. In: Kasper DL, Braunwald E, Fauci AS, Hauser SL, Longo DL, Jameson JL, eds. Harrison's principles of internal medicine. 16th ed. New York, NY: McGraw Hill, 2005:1076-139.
7. Fauci AS, Pantaleo G, Stanley S, Weissman D. Immunopathogenic mechanisms of HIV infection. Ann Intern Med 1996; 124:654-63.
8. Brenchley JM, Price DA, Douek DC. HIV disease: fallout from a mucosal catastrophe? Nat Immunol 2006; 7:235-9.
9. Galvin SR, Cohen MS. The role of sexually transmitted diseases in HIV transmission. Nat Rev Microbiol 2004; 2:33-42.
10. Reynolds SJ, Risbud AR, Shepherd ME, et al. High rates of syphilis among STI patients are contributing to the spread of HIV-1 in India. Sex Transm Infect 2006; 82:121-6.
11. Reynolds SJ, Risbud AR, Shepherd ME, et al. Recent herpes simplex virus type 2 infection and the risk of human immunodeficiency virus type 1 acquisition in India. J Infect Dis 2003; 187:1513-21.
12. Hotez PJ, Molyneux DH, Stillwaggon E, Bentwich Z, Kumaresan J. Neglected tropical diseases and HIV/AIDS. Lancet 2006; 368:1865-6.
13. Bentwich Z, Maartens G, Torten D, Lal AA, Lal RB. Concurrent infections and HIV pathogenesis. AIDS 2000; 14:2071-81.
14. Borkow G, Bentwich Z. HIV and helminth co-infection: is deworming necessary? Parasite Immunol 2006; 28:605-12.
15. Gopinath R, Ostrowski M, Justement SJ, Fauci AS, Nutman TB. Filarial infections increase susceptibility to human immunodeficiency virus infection in peripheral blood mononuclear cells in vitro. J Infect Dis 2000; 182:1804-8.
16. Modjarrad K, Zulu I, Redden DT, Njobvu L, Lane HC, Bentwich Z, Vermund SH. Treatment of intestinal helminths does not reduce plasma concentrations of HIV-1 RNA in coinfected Zambian adults. J Infect Dis 2005; 192:1277-83.
17. Collins KR, Quinones-Mateu ME, Toossi Z, Arts EJ. Impact of tuberculosis on HIV-1 replication, diversity, and disease progression. AIDS Rev 2002; 4:165-76.
18. Goletti D, Weissman D, Jackson RW, et al. Effect of Mycobacterium tuberculosis on HIV replication: role of immune activation. J Immunol 1996; 157:1271-8.
19. Kublin JG, Patnaik P, Jere CS, et al. Effect of Plasmodium falciparum malaria on concentration of HIV-1-RNA in the blood of adults in rural Malawi: a prospective cohort study. Lancet 2005; 365:233-40.
20. Finley BM, Plescia CJ, Harrison PF, des Vignes FN. An analytical overview of the microbicide preclinical and clinical pipeline [poster]. In: Program and abstracts of the XVI International AIDS Conference (Toronto, Canada). 2006. Available at: http://www.microbicide.org/microbicideinfo/reference/ AMD.AIDS2006.PosterPresentation.7Aug 06.pdf. Accessed 26 February 2007.
21. Moore JP. Topical microbicides become topical. N Engl J Med 2005;352:298-300.
22. Weiss HA, Quigley MA, Hayes RJ. Male circumcision and risk of HIV infection in sub-Saharan Africa: a systematic review and meta-analysis. AIDS 2000; 14:2361-70.
23. Bailey RC, Moses S, Parker CB, et al. Male circumcision for HIV prevention in young men in Kisumu, Kenya: a randomized controlled trial. Lancet 2007; 369:643-56.
24. Gray RH, Kigozi G, Serwadda D, et al. Male circumcision for HIV prevention in men in Rakai, Uganda: a randomized trial. Lancet 2007; 369:657-66.
25. Auvert B, Taljaard D, Lagarde E, Sobngwi-Tambekou J, Sitta R, Puren A. Randomized, controlled intervention trial of male circumcision for reduction of HIV infection risk: the ANRS 1265 Trial. PLoS Med 2005; 2:e298 (erratum: PLoS Med 2006; 3:e298).
26. Szabo R, Short RV. How does male circumcision protect against HIV infection? BMJ 2000; 320:1592-4.
27. Centers for Disease Control and Prevention (CDC). Male circumcision and risk for HIV transmission: implications for the United States. Atlanta, GA: US Department of Health and Human Services, CDC, 2007. Available at: http://www.cdc.gov/hiv/resources/factsheets/PDF/circumcision.pdf. Accessed 9 September 2007.
28. Youle M, Wainberg MA. Could chemoprophylaxis be used as an HIV prevention strategy while we wait for an effective vaccine? AIDS 2003; 17:937-8.
29. Centers for Disease Control and Prevention (CDC). CDC trials of pre-exposure prophylaxis for HIV prevention. Atlanta, GA: US Department of Health and Human Services, CDC, 2007. Available at: http://www.cdc.gov/ hiv/resources/factsheets/prep.htm. Accessed 9 September 2007.
30. Grant RM, Wainberg MA. Chemoprophylaxis of HIV infection: moving forward with caution. J Infect Dis 2006; 194:874-6.
31. US Department of Health and Human Services Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. 10 October 2006. Available at: http://aidsinfo.nih.gov/contentfiles/Adultand AdolescentGL.pdf. Accessed 26 March 2007.
32. Smith DK, Grohskopf LA, Black RJ, et al. Antiretroviral postexposure prophylaxis after sexual, injection-drug use, or other nonoccupational exposure to HIV in the United States: recommendations from the US Department of Health and Human Services. US Department of Health and Human Services. MMWR Recomm Rep 2005; 54(RR-2):1-20.
33. Panlilio AL, Cardo DM, Grohskopf LA, Heneine W, Ross CS. Updated US Public Health Service guidelines for the management of occupational exposures to HIV and recommendations for postexposure prophylaxis. US Public Health Service. MMWR Recomm Rep 2005; 54(RR-9):1-17.
34. Cooper ER, Charurat M, Mofenson L, et al. Combination antiretroviral strategies for the treatment of pregnant HIV-1-infected women and prevention of perinatal HIV-1 transmission. Women and Infants' Transmission Study Group. J Acquir Immune Defic Syndr 2002; 29:484-94.
35. Quinn TC, Wawer MJ, Sewankambo N, et al. Viral load and heterosexual transmission of human immunodeficiency virus type 1. Rakai Project Study Group. N Engl J Med 2000; 342:921-9.
36. Gray RH, Wawer MJ, Brookmeyer R, et al. Probability of HIV-1 transmission per coital act in monogamous, heterosexual, HIV-1-discordant couples in Rakai, Uganda. Rakai Project Team. Lancet 2001; 357:1149-53.
37. Wawer MJ, Gray RH, Sewankambo NK, et al. Rates of HIV-1 transmission per coital act, by stage of HIV-1 infection, in Rakai, Uganda. J Infect Dis 2005; 191:1403-9.
38. Douek DC, Kwong PD, Nabel GJ. The rational design of an AIDS vaccine. Cell 2006; 124:677-81.
39. Letvin NL. Progress and obstacles in the development of an AIDS vaccine. Nat Rev Immunol 2006; 6:930-9.
40. Wilson NA, Reed J, Napoe GS, et al. Vaccine-induced cellular immune responses reduce plasma viral concentration after repeated low-dose challenge with pathogenic simian immunodeficiency virus SIV mac239. J Virol 2006; 80:5875-85.